Investor Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel.

• The U.S. contraceptive market was estimated at $8.3 billion as of 2022.
• Every 1% market share of the 43.3 million women in our addressable market represents more than $450 million in net product sales for Evofem.
• 2023 marked the third consecutive year of Phexxi net sales growth.  

Evofem intends to expand Phexxi's global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

On December 11, 2023, Evofem and Aditxt, Inc. (Nasdaq: ADTX) entered into the Agreement and Plan of Merger by and between the companies (the "Merger Agreement"). On May 3, 2024, Evofem and Aditxt reinstated the Merger Agreement, as amended, and entered into the Fourth Amendment to the Agreement and Plan of Merger. The companies are working toward close in the second half of 2024.

Evofem believes the proposed Transaction represents a compelling opportunity to accelerate its growth trajectory, as a subsidiary of Aditxt, into a multi-product women's health franchise.

The Company's common stock currently trades on the OTCQB Venture Market under the ticker symbol "EVFM".